Momenta Pharmaceuticals (MNTA) Given News Sentiment Score of 0.22
Media headlines about Momenta Pharmaceuticals (NASDAQ:MNTA) have been trending somewhat positive this week, Alpha One Sentiment reports. The research firm, a service of Accern, ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Momenta Pharmaceuticals earned a coverage optimism score of 0.22 on Alpha One’s scale. Alpha One also gave media headlines about the biotechnology company an impact score of 80 out of 100, indicating that recent news coverage is likely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected AlphaOne Sentiment’s rankings:
- Investors Purchase High Volume of Momenta Pharmaceuticals Put Options (MNTA) (americanbankingnews.com)
- Mylan In FDA Limbo On Generic Multiple Sclerosis Drug (finance.yahoo.com)
- Implied Volatility Surging for Momenta Pharmaceuticals (MNTA) Stock Options (finance.yahoo.com)
- ETFs with exposure to Momenta Pharmaceuticals, Inc. : June 12, 2017 (finance.yahoo.com)
MNTA has been the topic of a number of research analyst reports. TheStreet upgraded Momenta Pharmaceuticals from a “d” rating to a “c” rating in a research note on Tuesday, February 21st. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 24th. Aegis restated a “hold” rating and issued a $17.00 target price on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 3rd. Barclays PLC downgraded Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $20.00 to $17.00 in a research note on Monday, May 22nd. Finally, Cowen and Company restated a “hold” rating and issued a $15.00 target price on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Momenta Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $16.89.
Momenta Pharmaceuticals (MNTA) traded up 2.15% during trading on Friday, reaching $16.65. The company had a trading volume of 1,016,606 shares. The firm’s 50 day moving average price is $15.48 and its 200 day moving average price is $15.17. Momenta Pharmaceuticals has a 12-month low of $9.66 and a 12-month high of $19.90. The firm’s market capitalization is $1.17 billion.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $0.63. Momenta Pharmaceuticals had a negative net margin of 24.70% and a negative return on equity of 8.20%. The company had revenue of $26.61 million for the quarter, compared to analysts’ expectations of $21.29 million. During the same quarter last year, the company posted ($0.35) earnings per share. The firm’s quarterly revenue was up 34.1% on a year-over-year basis. Equities research analysts forecast that Momenta Pharmaceuticals will post ($1.45) EPS for the current year.
In related news, President Craig A. Wheeler sold 1,852 shares of the firm’s stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $15.77, for a total value of $29,206.04. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $15.83, for a total transaction of $65,156.28. Following the completion of the sale, the president now owns 281,919 shares in the company, valued at approximately $4,462,777.77. The disclosure for this sale can be found here. Insiders sold 8,379 shares of company stock worth $131,825 in the last 90 days. 4.40% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This article was first published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.financial-market-news.com/2017/06/17/momenta-pharmaceuticals-mnta-given-news-sentiment-score-of-0-22.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.